Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Lilly confirms date and conference call for first-quarter 2025 financial results announcement
10:00am, Thursday, 17'th Apr 2025
INDIANAPOLIS , April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that da
S&P500 and Dow Jones: UnitedHealth Drops 19%, Eli Lilly Jumps on Trial Results
09:49am, Thursday, 17'th Apr 2025
S&P and Nasdaq futures rebound while Dow lags as UnitedHealth sinks 19% on earnings miss; Eli Lilly and Hertz post big premarket gains.
Eli Lilly shares surge on strong trial results for weight-loss pill
09:02am, Thursday, 17'th Apr 2025
Eli Lilly and Co (NYSE:LLY) shares jumped 12% in premarket trading on Thursday after the drugmaker said its experimental weight-loss pill, orforglipron, succeeded in a late-stage trial in patients wit
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics
09:00am, Thursday, 17'th Apr 2025
SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences (“BigHat”), a biotechnology company with a machine learning (ML)-guided antibody discovery and development platform, announced a strategic co
Eli Lilly stock surges 11% on obesity pill's success in first late-stage trial
08:37am, Thursday, 17'th Apr 2025
Eli Lilly's experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company's standing in the fast-growing market for weight loss and diabetes t
Lilly's pill helps diabetes patients lose 7.9% weight in crucial study
08:01am, Thursday, 17'th Apr 2025
(Reuters) -Eli Lilly said on Thursday its experimental pill, orforglipron, led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes in a late-stage
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
07:58am, Thursday, 17'th Apr 2025
Eli Lilly And Co LLY stock is trading higher on Thursday after the U.S. healthcare giant reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2
Eli Lilly's weight loss pill succeeds in first late-stage trial on diabetes patients
07:31am, Thursday, 17'th Apr 2025
CNBC's Angelica Peebles reports on the latest news from Eli Lilly.
Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.
07:24am, Thursday, 17'th Apr 2025
The pharmaceuticals company says a trial of the pill showed it was similarly safe to injectable weight-loss drugs.
Eli Lilly's stock soars 13% after reporting positive data from trial of diabetes and weight-loss pill
07:15am, Thursday, 17'th Apr 2025
Eli Lilly & Co.'s Inc.'s stock soared 13% in premarket trade Thursday, after the drug maker reported positive results from a late-stage trial of an oral GLP-1 treatment for Type 2 diabetes.
Lilly pill leads to 7.9% weight loss at 40 weeks in trial
06:50am, Thursday, 17'th Apr 2025
Eli Lilly said on Thursday its experimental pill, orforglipron, led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial.
Eli Lilly's weight loss pill succeeds in first late-stage trial on diabetes patients
06:45am, Thursday, 17'th Apr 2025
Eli Lilly said its daily obesity pill met the company's goals in the first of several closely watched late-stage trials. The pill helped Type 2 diabetes patients lower their blood sugar and body weigh
Eli Lilly's experimental GLP-1 pill met its study goals, helping diabetes patients lower blood sugar and even lose weight
06:45am, Thursday, 17'th Apr 2025
The drug helped lower patients' blood sugar and reduce their weight by an average of 16 pounds.
Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced weight
Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs
12:51pm, Wednesday, 16'th Apr 2025
What Johnson & Johnson and Eli Lilly are saying about Trump's pharmaceutical tariffs, and Dexcom scores FDA approval for its glucose monitoring system.
